University of Nebraska Medical Center and ANANDA Scientific announce USFDA approval
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
The drug will be available in 600 hospitals and 105 DTPs
It is developing the drug candidate to potentially treat immunological diseases
In clinical trials, treatment proved more effective than other therapies evaluated
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The plan is to advance innovative therapies to drug-resistant cancers
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Subscribe To Our Newsletter & Stay Updated